 | |
 | |
| Clinical data | |
|---|---|
| Other names | 5,6-Methylenedioxy-N-methyl-2-aminoindane; MDMAI |
| Drug class | Serotonin releasing agent;Entactogen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C11H13NO2 |
| Molar mass | 191.230 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
MDMAI, also known as5,6-methylenedioxy-N-methyl-2-aminoindane, is adrug of the2-aminoindane family developed in the 1990s by a team led byDavid E. Nichols atPurdue University.[1][2] It acts as a non-neurotoxicserotonin releasing agent (SRA) in animals and is a putativeentactogen in humans.[1][2]
MDMAI was first described in thescientific literature byDavid E. Nichols and colleagues in 1990.[1][2]
MDMAI can be thought of as acyclizedanalogue ofMDMA where the α-methyl group of the alkylamino side chain has been joined back round to the 6-position of the aromatic ring to form anindane ring system. This changes the core structure of the molecule fromphenethylamine to2-aminoindane, and causes the pharmacological properties of the two compounds to be substantially different.[2]
